Skip to content
XPR – Lifestyle Demo
Author:
Aura Biosciences, Inc.
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
June 1, 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 19, 2026
Aura Biosciences to Participate in Upcoming Investor Conferences
May 12, 2026
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
May 11, 2026
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 5, 2026
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
May 4, 2026
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 4, 2026
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
May 4, 2026
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 30, 2026